The American Journal of Human Genetics, ISSN 0002-9297, 10/2014, Volume 95, Issue 4, pp. 462 - 471
Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify...
SET | VARIANTS | CLASS-I | SNPS | RISK | UNIVERSITY | EXPRESSION | PEPTIDE | RESOURCE | TOOL | GENETICS & HEREDITY | Haplotypes - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Lymphoma, Follicular - genetics | Chromosomes, Human - genetics | Humans | Alleles | Polymorphism, Single Nucleotide - genetics | Biomarkers, Tumor - genetics | HLA Antigens - genetics | Case-Control Studies | Physiological aspects | Genome-wide association studies | Genetic aspects | Lymphatic diseases | Analysis | Report | Basic Medicine | Medical Genetics | Medicinsk genetik | Medical and Health Sciences | Medicin och hƤlsovetenskap | Medicinska och farmaceutiska grundvetenskaper
SET | VARIANTS | CLASS-I | SNPS | RISK | UNIVERSITY | EXPRESSION | PEPTIDE | RESOURCE | TOOL | GENETICS & HEREDITY | Haplotypes - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Lymphoma, Follicular - genetics | Chromosomes, Human - genetics | Humans | Alleles | Polymorphism, Single Nucleotide - genetics | Biomarkers, Tumor - genetics | HLA Antigens - genetics | Case-Control Studies | Physiological aspects | Genome-wide association studies | Genetic aspects | Lymphatic diseases | Analysis | Report | Basic Medicine | Medical Genetics | Medicinsk genetik | Medical and Health Sciences | Medicin och hƤlsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2459 - 2460
TRIAL | PLUS CYCLOPHOSPHAMIDE | PLACEBO | THERAPY | ONCOLOGY | R-CHOP | RITUXIMAB | VINCRISTINE | DOXORUBICIN | ELDERLY-PATIENTS | CHEMOTHERAPY
Journal Article
Oncotarget, ISSN 1949-2553, 03/2016, Volume 7, Issue 11, pp. 13260 - 13264
Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis....
Pembrolizumab | PD-1 inhibitors | Allogeneic stem cell transplantation | Immunotherapy | Hodgkin lymphoma
Pembrolizumab | PD-1 inhibitors | Allogeneic stem cell transplantation | Immunotherapy | Hodgkin lymphoma
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2005, Volume 23, Issue 26, pp. 6409 - 6414
Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older...
PHASE-II TRIAL | ANTI-CD20 MONOCLONAL-ANTIBODY | PROSPECTIVE RANDOMIZED-TRIAL | PROGNOSTIC-FACTORS | ONCOLOGY | PROGRESSION-FREE SURVIVAL | IN-SITU HYBRIDIZATION | LONG-TERM REMISSION | NON-HODGKINS-LYMPHOMA | PROTEASOME INHIBITOR BORTEZOMIB | PERIPHERAL-BLOOD | Severity of Illness Index | Prognosis | Drug Administration Schedule | Humans | Lymphoma, Mantle-Cell - pathology | Male | Treatment Outcome | Combined Modality Therapy | Doxorubicin | Vincristine | Patient Selection | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Lymphoma, Mantle-Cell - mortality | Cyclophosphamide | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Female | Hematopoietic Stem Cell Transplantation - methods | Prednisolone
PHASE-II TRIAL | ANTI-CD20 MONOCLONAL-ANTIBODY | PROSPECTIVE RANDOMIZED-TRIAL | PROGNOSTIC-FACTORS | ONCOLOGY | PROGRESSION-FREE SURVIVAL | IN-SITU HYBRIDIZATION | LONG-TERM REMISSION | NON-HODGKINS-LYMPHOMA | PROTEASOME INHIBITOR BORTEZOMIB | PERIPHERAL-BLOOD | Severity of Illness Index | Prognosis | Drug Administration Schedule | Humans | Lymphoma, Mantle-Cell - pathology | Male | Treatment Outcome | Combined Modality Therapy | Doxorubicin | Vincristine | Patient Selection | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Lymphoma, Mantle-Cell - mortality | Cyclophosphamide | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Female | Hematopoietic Stem Cell Transplantation - methods | Prednisolone
Journal Article
Blood, ISSN 0006-4971, 2019, Volume 133, Issue 24, pp. 2570 - 2574
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but...
1ST-LINE TREATMENT | PHASE-II TRIAL | MULTICENTER | SINGLE-AGENT TEMSIROLIMUS | RITUXIMAB | IBRUTINIB | TYROSINE KINASE INHIBITOR | FOLLOW-UP | INVESTIGATORS CHOICE | OPEN-LABEL | HEMATOLOGY
1ST-LINE TREATMENT | PHASE-II TRIAL | MULTICENTER | SINGLE-AGENT TEMSIROLIMUS | RITUXIMAB | IBRUTINIB | TYROSINE KINASE INHIBITOR | FOLLOW-UP | INVESTIGATORS CHOICE | OPEN-LABEL | HEMATOLOGY
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 12/2013, Volume 54, Issue 12, pp. 2586 - 2587
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2809 - 2809
Background Follicular lymphoma (FL) is the second most common lymphoma accounting for approximately 15% of all non-Hodgkin's lymphoma (NHL). Yttrium-90...
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1544 - 1544
Background MZL is a low-grade non-Hodgkin's lymphoma (NHL) which involves lymph nodes, extranodal sites, or spleen. It is sensitive to radiation therapy, which...
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2811 - 2811
Background: FDG PET/CT and bone marrow biopsy (BMB) are considered standard procedures for the staging of patients with new, untreated FL. A key issue in FL is...
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 12/2013, Volume 54, Issue 12, pp. 2586 - 2587
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 29, pp. 3688 - 3695
Purpose Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-cell transplantation have improved the outcome for...
MULTIPLE-MYELOMA | TRIAL | HYPER-CVAD | PLUS DEXAMETHASONE | ONCOLOGY | FREE SURVIVAL | RITUXIMAB | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CLASSIFICATION | TRANSPLANTATION | Thalidomide - adverse effects | Recurrence | Bortezomib | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Disease Progression | Lymphoma, Mantle-Cell - mortality | Thalidomide - analogs & derivatives | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Aged | Thalidomide - therapeutic use | ORIGINAL REPORTS | Hema15
MULTIPLE-MYELOMA | TRIAL | HYPER-CVAD | PLUS DEXAMETHASONE | ONCOLOGY | FREE SURVIVAL | RITUXIMAB | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CLASSIFICATION | TRANSPLANTATION | Thalidomide - adverse effects | Recurrence | Bortezomib | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Disease Progression | Lymphoma, Mantle-Cell - mortality | Thalidomide - analogs & derivatives | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Aged | Thalidomide - therapeutic use | ORIGINAL REPORTS | Hema15
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 3, pp. 294 - 296
ADVANCED-STAGE | PHASE-II TRIAL | POLICY | LOW-TUMOR-BURDEN | THERAPY | ONCOLOGY | REFRACTORY LOW-GRADE | NON-HODGKINS-LYMPHOMA | I-131 TOSITUMOMAB | RANDOMIZED CONTROLLED-TRIAL | Humans | Radioimmunotherapy - methods | Antibodies, Monoclonal - therapeutic use | Female | Lymphoma, Follicular - radiotherapy | Male | Antineoplastic Agents - therapeutic use
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 81 - 81
Abstract Long noncoding RNAs (lncRNAs) are defined as RNA-like transcripts that are over 200 nucleotides and lack significant open reading frames. Some lncRNAs...
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
In 101 patients with refractory large B-cell lymphoma, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel) resulted in an...
TRANSPLANT-ELIGIBLE PATIENTS | MEDICINE, GENERAL & INTERNAL | CYTOKINE RELEASE SYNDROME | REMISSIONS | CHIMERIC-ANTIGEN-RECEPTOR | NON-HODGKINS-LYMPHOMA | SALVAGE-CHEMOTHERAPY | OUTCOMES | LEUKEMIA | Immunotherapy, Adoptive | Interleukins - blood | Humans | Middle Aged | Receptors, Antigen, T-Cell - therapeutic use | Male | Survival Rate | Biomarkers - blood | T-Lymphocytes - transplantation | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Receptors, Antigen, T-Cell - blood | Adult | Antigens, CD19 | Female | Nervous System Diseases - chemically induced | T-Lymphocytes - immunology | Aged | Neutropenia - chemically induced | Treatment outcome | Care and treatment | Lymphocytic leukemia | Analysis | Thrombocytopenia | CD19 antigen | Cytokines | Body weight | Clinical trials | Lymphocytes T | Patients | Cancer therapies | Studies | Cyclophosphamide | Chemotherapy | Fludarabine | Lymphocytes B | Lymphocytes | Medical prognosis | Myelosuppression | Lymphomas | Drug dosages | Neutropenia | B-cell lymphoma
TRANSPLANT-ELIGIBLE PATIENTS | MEDICINE, GENERAL & INTERNAL | CYTOKINE RELEASE SYNDROME | REMISSIONS | CHIMERIC-ANTIGEN-RECEPTOR | NON-HODGKINS-LYMPHOMA | SALVAGE-CHEMOTHERAPY | OUTCOMES | LEUKEMIA | Immunotherapy, Adoptive | Interleukins - blood | Humans | Middle Aged | Receptors, Antigen, T-Cell - therapeutic use | Male | Survival Rate | Biomarkers - blood | T-Lymphocytes - transplantation | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Receptors, Antigen, T-Cell - blood | Adult | Antigens, CD19 | Female | Nervous System Diseases - chemically induced | T-Lymphocytes - immunology | Aged | Neutropenia - chemically induced | Treatment outcome | Care and treatment | Lymphocytic leukemia | Analysis | Thrombocytopenia | CD19 antigen | Cytokines | Body weight | Clinical trials | Lymphocytes T | Patients | Cancer therapies | Studies | Cyclophosphamide | Chemotherapy | Fludarabine | Lymphocytes B | Lymphocytes | Medical prognosis | Myelosuppression | Lymphomas | Drug dosages | Neutropenia | B-cell lymphoma
Journal Article
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 05/2005, Volume 55, Issue 3, pp. 178 - 194
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to control cell proliferation or in response to DNA damage. The understanding...
PROGRAMMED CELL-DEATH | MULTIPLE-MYELOMA | PHASE-II TRIAL | SURVIVIN EXPRESSION | ONCOLOGY | PROTEASOME INHIBITION | PROSTATE-CANCER | BCL-2 FAMILY-MEMBERS | NF-KAPPA-B | ACUTE PROMYELOCYTIC LEUKEMIA | ARSENIC TRIOXIDE | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | Membrane Glycoproteins - pharmacology | Neoplasms - enzymology | Antibodies, Monoclonal - therapeutic use | Drug Delivery Systems | Neoplasms - drug therapy | Tumor Necrosis Factor-alpha - pharmacology | Tumor Necrosis Factor-alpha - therapeutic use | Apoptosis Regulatory Proteins | Membrane Glycoproteins - therapeutic use | TNF-Related Apoptosis-Inducing Ligand | Signal Transduction - drug effects | Phosphatidylinositol 3-Kinases - drug effects | Apoptosis - physiology | Neoplasms - physiopathology | Research | Cancer | Apoptosis | Proteins | Medical treatment | Cells
PROGRAMMED CELL-DEATH | MULTIPLE-MYELOMA | PHASE-II TRIAL | SURVIVIN EXPRESSION | ONCOLOGY | PROTEASOME INHIBITION | PROSTATE-CANCER | BCL-2 FAMILY-MEMBERS | NF-KAPPA-B | ACUTE PROMYELOCYTIC LEUKEMIA | ARSENIC TRIOXIDE | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | Membrane Glycoproteins - pharmacology | Neoplasms - enzymology | Antibodies, Monoclonal - therapeutic use | Drug Delivery Systems | Neoplasms - drug therapy | Tumor Necrosis Factor-alpha - pharmacology | Tumor Necrosis Factor-alpha - therapeutic use | Apoptosis Regulatory Proteins | Membrane Glycoproteins - therapeutic use | TNF-Related Apoptosis-Inducing Ligand | Signal Transduction - drug effects | Phosphatidylinositol 3-Kinases - drug effects | Apoptosis - physiology | Neoplasms - physiopathology | Research | Cancer | Apoptosis | Proteins | Medical treatment | Cells
Journal Article
Cancer Research, ISSN 0008-5472, 07/2009, Volume 69, Issue 13, pp. 5522 - 5530
Journal Article
17.
Full Text
Work-Life Balance Solutions for PhysiciansāIt's All About You, Your Work, and Others
Mayo Clinic Proceedings, ISSN 0025-6196, 04/2019, Volume 94, Issue 4, pp. 573 - 576
The issue of physician burnout has received substantial attention in the medical literature and the workplace. Less attention has been paid to prevention....
MEDICINE, GENERAL & INTERNAL | Psychological aspects | Social aspects | Physicians | Health aspects | Work-life balance | Insurance industry | Medicine | Work life balance | Hematology | Families & family life | Careers | Outbreaks | Workloads | Lymphomas | Lymphoma | Electronic medical records | Children & youth
MEDICINE, GENERAL & INTERNAL | Psychological aspects | Social aspects | Physicians | Health aspects | Work-life balance | Insurance industry | Medicine | Work life balance | Hematology | Families & family life | Careers | Outbreaks | Workloads | Lymphomas | Lymphoma | Electronic medical records | Children & youth
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 251 - 257
Purpose Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely...
MULTIPLE-MYELOMA | TRIAL | SURVIVAL | THROMBOTIC COMPLICATIONS | ONCOLOGY | MACOP-B | NON-HODGKINS-LYMPHOMA | STANDARD REGIMEN CHOP | COMBINATION | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Thalidomide - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use
MULTIPLE-MYELOMA | TRIAL | SURVIVAL | THROMBOTIC COMPLICATIONS | ONCOLOGY | MACOP-B | NON-HODGKINS-LYMPHOMA | STANDARD REGIMEN CHOP | COMBINATION | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Thalidomide - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 9619 - 9619
Journal Article
Blood, ISSN 0006-4971, 01/2011, Volume 117, Issue 3, pp. 872 - 881
Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully...
FOLLICULAR LYMPHOMAS | MYELOID SUPPRESSOR-CELLS | HEPATOCELLULAR-CARCINOMA | PERIPHERAL-BLOOD | COUNT PREDICTS | LYMPHOPROLIFERATIVE DISORDERS | HEMATOLOGY | HLA-DR EXPRESSION | PREDICTS THERAPEUTIC-EFFICACY | T-CELLS | ENDOTHELIAL GROWTH-FACTOR | Lymphoid Neoplasia
FOLLICULAR LYMPHOMAS | MYELOID SUPPRESSOR-CELLS | HEPATOCELLULAR-CARCINOMA | PERIPHERAL-BLOOD | COUNT PREDICTS | LYMPHOPROLIFERATIVE DISORDERS | HEMATOLOGY | HLA-DR EXPRESSION | PREDICTS THERAPEUTIC-EFFICACY | T-CELLS | ENDOTHELIAL GROWTH-FACTOR | Lymphoid Neoplasia
Journal Article